Effects of the combination of TRC105 and bevacizumab on endothelial cell biology
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Effects of the combination of TRC105 and bevacizumab on endothelial cell biology
Authors
Keywords
TRC105, Endoglin, Bevacizumab, Angiogenesis, Endothelial cells
Journal
INVESTIGATIONAL NEW DRUGS
Volume 32, Issue 5, Pages 851-859
Publisher
Springer Nature
Online
2014-07-04
DOI
10.1007/s10637-014-0129-y
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Recent Advances in Anti-Angiogenic Therapy of Cancer
- (2015) Rajeev S. Samant et al. Oncotarget
- Deficiency for endoglin in tumor vasculature weakens the endothelial barrier to metastatic dissemination
- (2013) Charlotte Anderberg et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Anti-angiogenesis therapy in cancer: Current challenges and future perspectives
- (2012) Farbod Shojaei CANCER LETTERS
- A Phase I First-in-Human Study of TRC105 (Anti-Endoglin Antibody) in Patients with Advanced Cancer
- (2012) L. S. Rosen et al. CLINICAL CANCER RESEARCH
- Antiangiogenic therapy—evolving view based on clinical trial results
- (2012) Gordon C. Jayson et al. Nature Reviews Clinical Oncology
- Structural and Functional Insights into Endoglin Ligand Recognition and Binding
- (2012) Aaron Alt et al. PLoS One
- Endoglin Requirement for BMP9 Signaling in Endothelial Cells Reveals New Mechanism of Action for Selective Anti-Endoglin Antibodies
- (2012) Olivier Nolan-Stevaux et al. PLoS One
- Soluble Endoglin Specifically Binds Bone Morphogenetic Proteins 9 and 10 via Its Orphan Domain, Inhibits Blood Vessel Formation, and Suppresses Tumor Growth
- (2011) Roselyne Castonguay et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Bevacizumab: current updates in treatment
- (2010) Margaret EM Van Meter et al. CURRENT OPINION IN ONCOLOGY
- Evading tumor evasion: Current concepts and perspectives of anti-angiogenic cancer therapy
- (2010) Amir Abdollahi et al. DRUG RESISTANCE UPDATES
- Endoglin-Targeted Cancer Therapy
- (2010) Ben K. Seon et al. Current Drug Delivery
- Targeting cancer vasculature via endoglin/CD105: a novel antibody-based diagnostic and therapeutic strategy in solid tumours
- (2009) E. Fonsatti et al. CARDIOVASCULAR RESEARCH
- Receptor-targeted anticancer therapy
- (2009) Ben K. Seon et al. IMMUNOLOGIC RESEARCH
- Endoglin (CD105): A Marker of Tumor Vasculature and Potential Target for Therapy
- (2008) N. A. Dallas et al. CLINICAL CANCER RESEARCH
- Anti-tumor activity of an anti-endoglin monoclonal antibody is enhanced in immunocompetent mice
- (2008) Masanori Tsujie et al. INTERNATIONAL JOURNAL OF CANCER
- Endoglin Promotes Transforming Growth Factor β-mediated Smad 1/5/8 Signaling and Inhibits Endothelial Cell Migration through Its Association with GIPC
- (2008) Nam Y. Lee et al. JOURNAL OF BIOLOGICAL CHEMISTRY
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started